AUG 7·SEC EDGARLow
Cho Dennis sold $1.6M of TWST
Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $109.75 ($1.56M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$TWST
Twist Bioscience Corp
Price · $TWSTvia TradingView
AI sentiment · 7d6 articles
- Bullish
- 2
- Neutral
- 2
- Bearish
- 2
Top stories · $TWSTMore →
AUG 5·SEC EDGAR 8-K
Twist Bioscience Corp (TWST): Entry into a Material Definitive Agreement
Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2622018d2_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 TWIST BIOSCIENCE CORPORATION 3,125,000 Shares of Common Stock Underwriting Agreement August 4, 2026 Goldman Sachs & Co. LLC William Blair & Company, L.L.C. Leerink Partners LLC Guggenheim Securities, LLC As Representatives of
AUG 5·SEC EDGAR
Finn Patrick John sold $246K of TWST
Finn Patrick John (President and COO) sold 2,888 shares of Twist Bioscience Corp (TWST) at $85.32 ($0.25M total) on 2026-08-03.
TWST sentiment & insider activity
Over the past 7 days, alphai's AI scored 6 news stories mentioning TWST (Twist Bioscience Corp). Coverage has been balanced: 2 bullish, 2 neutral, and 2 bearish.
Recent TWST coverage spans insider activity, corporate actions and earnings.
In the last 30 days, TWST insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($2.9M). The most active reporter was Finn Patrick John, President and COO, with 2 filings. 12% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving TWST
This is a routine, pre-planned insider sale disclosure; it may slightly affect sentiment but is not a fundamental catalyst by itself.
The 8-K discloses a new equity offering structure and pricing, which can pressure near-term supply-demand and sentiment.
This is a routine insider open-market sale with no 10b5-1 plan disclosed, but it is not a fundamental company disclosure.
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
The dilutive equity raise is likely to pressure near-term valuation, but provides funding for R&D and manufacturing expansion.
alphai scores every news story that mentions TWST with an AI model for sentiment and relevance, and aggregates insider trades from Twist Bioscience Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TWST
Score
Cho Dennis sold $1.6M of TWST
Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $109.75 ($1.56M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readTwist Bioscience Corp (TWST): Entry into a Material Definitive Agreement
Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2622018d2_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 TWIST BIOSCIENCE CORPORATION 3,125,000 Shares of Common Stock Underwriting Agreement August 4, 2026 Goldman Sachs & Co. LLC William Blair & Company, L.L.C. Leerink Partners LLC Guggenheim Securities, LLC As Representatives of
3 min readFinn Patrick John sold $246K of TWST
Finn Patrick John (President and COO) sold 2,888 shares of Twist Bioscience Corp (TWST) at $85.32 ($0.25M total) on 2026-08-03.
1 min readLeproust Emily M. sold $435K of TWST
Leproust Emily M. (Chief Executive Officer) sold 5,101 shares of Twist Bioscience Corp (TWST) at $85.32 ($0.44M total) on 2026-08-03.
2 min read
Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering
Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.
3 min readTwist Bioscience Q3 Earnings Call Highlights
Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.
6 min readCathie Wood’s ARK sells AMD stock, buys CoreWeave and Kratos
According to Investing.com, Cathie Wood’s ARK ETFs reported May 8, 2026 trades. ARK sold Advanced Micro Devices (AMD) shares worth about $18.8 million and bought CoreWeave (CRWV) for about $14.6 million and Kratos Defense (KTOS) for about $9.6 million. It also bought Kodiak AI (KDK), X-Energy (XE), Cloudflare (NET) and Intellia (NTLA), while selling Rocket Lab (RKLB), Teradyne (TER) and Twist Bioscience (TWST).
3 min readWhy is Twist Bioscience stock sliding today?
Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.
3 min readTwist Bioscience Corp (TWST): Results of Operations and Financial Condition
Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth
4 min readProposed Settlement Reached in Twist Bioscience Securities Litigation
Simpluris, the court-appointed claims administrator, said a hearing on Nov. 18, 2026 will consider whether to approve a proposed $17.05 million cash settlement in Anthony Joseph Peters v. Twist Bioscience Corp. The case involves claims by purchasers of Twist common stock during specified periods. If approved, the litigation would be dismissed with prejudice and a plan of allocation and attorneys’ fees would be reviewed.
2 min read